Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
What is Middle East Pharmaceutical Industries Co Net Margin %?
Middle East Pharmaceutical Industries CoSAU:4016 +0.92%22 Net Margin % is 20.67% as of Mar. 2026, which is 2% above its 10-year median of 20.27. GuruFocus rates SAU:4016 with a GF Score™ of 22/100. The stock has 3 warning signs investors should review. Among 960 Drug Manufacturers companies, Middle East Pharmaceutical Industries Co ranks better than 88.33% on this metric.
SAU:4016'
s Net Margin % Range Over the Past 10 Years
Min: 19.45 Med: 20.27 Max: 21.19
Current: 21.19
SAU:4016's Net Margin % is ranked better than 88.33% of 960
companies
in the Drug Manufacturers industry
Industry Median: 5.635
vs SAU:4016: 21.19
Middle East Pharmaceutical Industries Co (SAU:4016) Net Margin % Explanation
Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.
But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.
Middle East Pharmaceutical Industries Co Net Margin % Related Terms
Middle East Pharmaceutical Industries Co Net Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Middle East Pharmaceutical Industries Co Net Margin % Chart
Middle East Pharmaceutical Industries Co Annual Data
Trend
Dec23
Dec24
Dec25
Net Margin %
19.45
20.27
21.07
Middle East Pharmaceutical Industries Co Quarterly Data
SAU:4016 vs ZTS, UTHR, VTRS: Net Margin % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Middle East Pharmaceutical Industries Co's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Middle East Pharmaceutical Industries Co Net Margin % vs Drug Manufacturers Industry
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Middle East Pharmaceutical Industries Co (SAU:4016) has a Net Margin % of 20.67% as of Mar. 2026. Net margin is the ratio of total net income to net sales. View historical data on Middle East Pharmaceutical Industries Co and its competitors. This is near median its historical median of 20.27. Over the past decade, Middle East Pharmaceutical Industries Co's Net Margin % has ranged from 19.45 to 21.19. According to the industry distribution chart, Middle East Pharmaceutical Industries Co ranks #112 out of 960 companies in the Drug Manufacturers industry, placing it in the top 11.7%.
Is Middle East Pharmaceutical Industries Co's Net Margin % too high?
Middle East Pharmaceutical Industries Co's current Net Margin % of 20.67% is near median its 10-year median of 20.27. Over the past 10 years, this metric has ranged from a low of 19.45 to a high of 21.19. The Drug Manufacturers industry median Net Margin % is 5.64. Middle East Pharmaceutical Industries Co's value of 20.67% is 266.8% above this industry median. Based on the distribution chart, Middle East Pharmaceutical Industries Co ranks #112 out of 960 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Middle East Pharmaceutical Industries Co has a GF Score™ of 22/100, reflecting its overall financial health beyond just this single metric.
How does Middle East Pharmaceutical Industries Co's Net Margin % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Middle East Pharmaceutical Industries Co ranks #112 out of 960 companies for Net Margin %. This places Middle East Pharmaceutical Industries Co in the top 12% of its industry — outperforming the majority of peers. The industry median Net Margin % is 5.64. Middle East Pharmaceutical Industries Co's value of 20.67% is 266.8% above this benchmark. Historically, Middle East Pharmaceutical Industries Co's own Net Margin % has ranged from 19.45 to 21.19 over the past decade. While the company's 10-year median is 20.27 vs. the industry median of 5.64, Middle East Pharmaceutical Industries Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Drug Manufacturers company?
The median Net Margin % among Drug Manufacturers companies is 5.64, based on 960 companies in the industry. Companies in the top quartile (top 25%) have a Net Margin % significantly above this median, while those in the bottom quartile fall well below. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Middle East Pharmaceutical Industries Co's current Net Margin % of 20.67% is 266.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on Middle East Pharmaceutical Industries Co and its competitors. For the Drug Manufacturers industry, the median Net Margin % is 5.64 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Middle East Pharmaceutical Industries Co's current Net Margin % is 20.67%, which is near median its own 10-year median of 20.27. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Middle East Pharmaceutical Industries Co stock overvalued right now?
Middle East Pharmaceutical Industries Co (SAU:4016) has a current Net Margin % of 20.67%. The current Net Margin % is 20.67%, which is near median its 10-year median of 20.27 and 266.8% above the Drug Manufacturers industry median of 5.64. Middle East Pharmaceutical Industries Co's overall GF Score™ is 22/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For Middle East Pharmaceutical Industries Co (SAU:4016), the current Net Margin % is 20.67% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Middle East Pharmaceutical Industries Co Business Description
Middle East Pharmaceutical Industries Co is a holding company engaged in manufacturing medicines, medicated and non-medicated creams and gels. The company operates in Private, Public, and Export segments. Geographically, it generates the majority of its revenue from Saudi Arabia.
22GF Score
Get the complete analysis for SAU:4016
Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SAU:4016 has been successfully added to your 
